Impact of a clinical pharmacist intervention on medicine costs in patients with chronic obstructive pulmonary disease in India

Suhaj Abdulsalim, Unnikrishnan Mazhuvancherry Kesavan, Manu K. Mohan, Saud Alsahali, Alian A. Alrasheedy, Antony P Martin, Brian Godman, Abubakr A Alfadl

Research output: Contribution to journalArticlepeer-review

37 Downloads (Pure)


Background: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality especially in lower and middle income countries (LMICs) such as India. Medicine costs are a key issue in LMICs with typically high patient co-payments. In addition, pharmacists are underutilised in LMICs including India. However, pharmacist-led educational interventions may improve the care of patients with COPD as well as reduce medicine costs. Consequently, the objective of this study was to assess the effectiveness of a pharmacist led intervention in reducing medicine costs. Methodology: We assessed the impact of a pharmacist intervention on direct medicine costs in COPD patients (medicine costs and pharmacist time) in a randomized controlled study involving an intervention and control group and conducted at a tertiary care teaching hospital in India. Results: The six-monthly cost of medicines at baseline increased with disease severity from a maximum of US$29.46 for those with mild COPD up to US$63.28 for those with very severe COPD. Substantial savings in medical costs were achieved with the pharmacist-led programme, up to a maximum of US$20.49 over six-months for very severe patients. This equates to a reduction of 30.6% in medicine costs (P < 0.001), reduced to 26.1% when pharmacists’ time (US$3.00/ patient) is included. Conclusion: There could be a key role for pharmacists as educators in COPD patients in LMICs to improve care and reduce costs including patient co-payments.
Original languageEnglish
Pages (from-to)331-342
Number of pages12
JournalPharmacoEconomics - Open
Early online date31 Jul 2019
Publication statusPublished - 30 Jun 2020


  • clinical pharmacist-led intervention
  • direct medical costs
  • COPD
  • India

Cite this